Journal of Thoracic Oncology · 2023 · 25 citations · 43 references
Life SciencesMolecular BiologyOncologyCancer GeneticsMolecular OncologyTranscriptomicsCancer BiomarkersCancer TranscriptomicsExpression Signature DiscoveryMolecular Tumor ProfilingMutational SignaturesTranscriptomic ProfilingActivating MutationsCancer Mutation Signature AnalysisCancer Mutation SignaturesMutational Signature BiomarkersTranscriptomic ProfilesTranscriptomic Signature DevelopmentTranscriptomic Signature DiscoveryTumor Profiling
INTRODUCTION: Activation of the antioxidant KEAP1/NFE2L2 (NRF2) pathway leads to increased glutamine dependence and an aggressive phenotype in NSCLC. Because this pathway has been explored as a clinical target, we developed a transcriptomic signature for identifying KEAP1/NFE2L2-activated tumors. METHODS: A total of 971 NSCLC samples were used to train an expression signature (K1N2-score) to predict KEAP1/NFE2L2 mutations. There were 348 in-house NSCLCs that were analyzed using a NanoString expression panel for validation. RESULTS: The 46-gene K1N2 score robustly predicted KEAP1/NFE2L2 mutations in the validation set irrespective of histology and mutation (area under the curve: 89.5, sensitivity: 90.2%), suggesting that approximately 90% of KEAP1/NFE2L2 mutations are pathway-activating. The K1N2-score outperformed KEAP1/NFE2L2 mutational status when predicting patient survival (score p = 0.047; mutation p = 0.215). In K1N2 score-positive but KEAP1/NFE2L2 wild-type samples, enrichment testing identified SMARCA4/BRG1 and CUL3 mutations as mimics of KEAP1/NFE2L2 mutations. CONCLUSIONS: The K1N2-score identified KEAP1/NFE2L2-activated NSCLC by robustly detecting KEAP1/NFE2L2mut cases and discovering alternative genomic activators. It is a potential means for selecting patients with a constitutively active KEAP1/NFE2L2 pathway.
43
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran, Zicheng Hu, Atul J. Butte · Genome biology · 2017 · 4.7K citations · Full text
Jianfang Liu, Tara M. Lichtenberg, Katherine A. Hoadley et al. · Cell · 2018 · 3.9K citations · Full text
Pharmacy, Bioinformatics, Oncology +14
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson, Jaegil Kim, Hikmat Al‐Ahmadie et al. · Cell · 2017 · 2.5K citations · Full text